Canaccord lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $66 from $68 and keeps a Buy rating on the shares. The firm said they remain focused on the company’s CF program, which is now expected to readout data in mid-2025 vs 2Q25 previous. Canaccord have updated its model for 1Q25 results, and adjusted revenue recognition timing for Kostaive from 4Q26 to 1Q27.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
- Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
- Arcturus Therapeutics: Promising Vaccine Rollout and Cystic Fibrosis Treatment Drive Buy Rating
- Arcturus Therapeutics Reports Q1 2025 Financial Update
- Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)